Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
eli lilly
5
×
fda
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
5
×
raleigh-durham top stories
amgen
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
migraine research foundation
teva pharmaceutical
abbvie
allergan
astrazeneca
avexis
bristol-myers squibb
calcitonin gene-related peptide
celgene
What
fda
5
×
drug
won
approval
migraine
new
bio
class
companies
decades
drugs
news
roundup
acute
addresses
amgen
approved
arguments
august
big
biotech
busy
candidates
causes
commercialized
competitors
condition
days
decisions
developed
devices
digital
disease
eli
epidemic
fatty
frenzied
friday
gets
giant
Language
unset
Current search:
fda
×
" raleigh-durham blog main "
×
" eli lilly "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines